LEADER 04947nam 2201273z- 450 001 9910557359303321 005 20231214132925.0 035 $a(CKB)5400000000042299 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77046 035 $a(EXLCZ)995400000000042299 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMalignant Mesothelioma 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (328 p.) 311 $a3-0365-2368-5 311 $a3-0365-2367-7 330 $aMalignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM?s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene?environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM?s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects. 606 $aMedicine$2bicssc 610 $awell-differentiated papillary mesothelioma 610 $aWDPM 610 $amalignant mesothelioma 610 $aDNA sequencing 610 $amutation 610 $amesothelioma 610 $atumor suppressor 610 $atargeted therapy 610 $aimmunotherapy 610 $abiomarkers 610 $aproteomics 610 $amacrophage-capping protein 610 $afatty acid-binding protein 610 $alaminin subunit beta-2 610 $aselenium-binding protein 1 610 $acarcinogenesis 610 $amalignant pleural mesothelioma 610 $aasbestos exposure 610 $aDNA methylation 610 $alymphocyte-to-monocyte ratio 610 $aepigenome-wide analysis 610 $asurvival analysis 610 $ametabolomics 610 $aradiotherapy 610 $acancers 610 $ainflammation 610 $ainfiltrating immune cells 610 $aprognostic biomarker 610 $apredictive biomarker 610 $aimmune therapy 610 $aVATS 610 $aextrapleural pneumonectomy 610 $apleurectomy decortication 610 $atherapy response 610 $asurvival 610 $aFDG 610 $aPET-CT 610 $amesothelium 610 $aoxidative stress 610 $aredox-sensitive factors 610 $aasbestos 610 $acarbon nanotubes 610 $aprotein-protein interactions 610 $asystems biology 610 $anetwork analysis 610 $adrug repurposing 610 $apleural mesothelioma 610 $agene expression 610 $aimmunogenicity 610 $asarcomatoid 610 $aepithelioid 610 $afirst line 610 $ameta-analysis 610 $asystematic review 610 $aMPM 610 $alurbinectedin 610 $aDNA damage response 610 $ahistotype 610 $aHippo pathway 610 $aNF2 610 $aBAP1 610 $aCDKN2A 610 $aPTCH1 610 $aSETD2 610 $aMTAP 610 $aliquid biopsies 610 $acirculating tumor DNA 610 $aplasma 610 $acancer-specific mutations 610 $agenomics 610 $acancer biomarkers 610 $atumor microenvironment 610 $atumor-associated macrophages 610 $adendritic cells 610 $aimmunohistochemistry 610 $ainteraction analysis 610 $apleural effusion 615 7$aMedicine 700 $aL. Pouliquen$b Daniel$4edt$01311333 702 $aKopecka$b Joanna$4edt 702 $aL. Pouliquen$b Daniel$4oth 702 $aKopecka$b Joanna$4oth 906 $aBOOK 912 $a9910557359303321 996 $aMalignant Mesothelioma$93030257 997 $aUNINA